Context Therapeutics (NASDAQ:CNTX) Now Covered by Guggenheim

Key Points

• Guggenheim has initiated coverage on Context Therapeutics (CNTX), assigning a "buy" rating and setting a price target of $5.00, indicating a potential upside of 471.43%.
• Other analysts have given mixed ratings, with HC Wainwright lowering their target to $4.00, while D. Boral Capital maintains a higher target of $9.00.
• Context Therapeutics reported a quarterly loss of ($0.09) earnings per share, which was below the consensus estimate of ($0.06).

Equities research analysts at Guggenheim began coverage on shares of Context Therapeutics (NASDAQ:CNTX - Get Free Report) in a note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $5.00 price target on the stock. Guggenheim's target price points to a potential upside of 471.43% from the company's current price.

Several other equities research analysts have also recently issued reports on CNTX. HC Wainwright decreased their price objective on Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Thursday, August 7th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $4.00 target price (down previously from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $5.20.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $0.88 on Thursday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.59. The company has a market capitalization of $78.49 million, a P/E ratio of -2.43 and a beta of 1.91. The business has a 50 day moving average price of $0.81 and a 200 day moving average price of $0.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03). On average, research analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in Context Therapeutics in the fourth quarter valued at approximately $31,000. Millennium Management LLC boosted its stake in Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after acquiring an additional 34,835 shares during the period. Finally, Jane Street Group LLC acquired a new position in Context Therapeutics in the fourth quarter valued at approximately $29,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.